MedTrace Logo

Genetic Variability and Biomarkers in Children With Acute Lung Injury

NCT01048996 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-08-24

No results posted yet for this study

Summary

Acute Lung Injury (ALI) and the more severe Acute Respiratory Distress Syndrome (ARDS) are a significant problem in Pediatric Intensive Care Units, affecting up to 16 of every 1000 children admitted to these units. These disorders carry with them high mortality rates as well as numerous long-term effects for the surviving children. As the effects of these diseases have significant social and economic ramifications for affected children and their families, research on the development of ALI/ARDS could significantly change how physicians understand the disease and treat patients.

There are a wide range of problems which make certain PICU patients more likely to develop either ALI or ARDS. This research aims to determine which of these children are at the greatest risk for ALI/ARDS by examining differences in plasma biomarkers and in DNA of a large number of PICU patients. We are hypothesizing that significant differences in the level of specific plasma biomarkers or in the frequency of specific DNA variants exist in children who develop ALI/ARDS.

Conditions

  • Acute Respiratory Distress Syndrome
  • Acute Lung Injury

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • UCSF Benioff Children's Hospital Oakland

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Michael Quasney, PhD, MD · Medical College of Wisconsin

Eligibility

Min Age
2 Weeks
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01048996 on ClinicalTrials.gov